Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)

Trial Profile

Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs B 001 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Shanghai Pharmaceuticals Holding
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Mar 2018 Planned End Date changed from 15 Oct 2019 to 18 Feb 2020.
    • 26 Mar 2018 Planned primary completion date changed from 25 Jul 2019 to 7 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top